Literature DB >> 15986139

Role of nuclear factor-kappa B in melanoma.

Katayoun I Amiri1, Ann Richmond.   

Abstract

Nuclear Factor-kappa B (NF-kappa B) is an inducible transcription factor that regulates the expression of many genes involved in the immune response. Recently, NF-kappa B activity has been shown to be upregulated in many cancers, including melanoma. Data indicate that the enhanced activation of NF-kappa B may be due to deregulations in upstream signaling pathways such as Ras/Raf, PI3K/Akt, and NIK. Multiple studies have shown that NF-kappa B is involved in the regulation of apoptosis, angiogenesis, and tumor cell invasion, all of which indicate the important role of NF-kappa B in tumorigenesis. Thus, understanding the molecular mechanism of melanoma progression will aid in designing new therapeutic approaches for melanoma. In this review, the association between NF-kappa B and melanoma tumorigenesis are discussed. Additionally, the potential of emerging selective NF-kappa B inhibitors for the treatment of melanoma is reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986139      PMCID: PMC2668255          DOI: 10.1007/s10555-005-1579-7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  123 in total

Review 1.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Authors:  Y Yamamoto; R B Gaynor
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.

Authors:  D Koul; Y Yao; J L Abbruzzese; W K Yung; S A Reddy
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

3.  2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway.

Authors:  L Deng; Y C Lin-Lee; F X Claret; M T Kuo
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

Review 4.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.

Authors:  G Xiao; E W Harhaj; S C Sun
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

6.  The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells.

Authors:  A V Franco; X D Zhang; E Van Berkel; J E Sanders; X Y Zhang; W D Thomas; T Nguyen; P Hersey
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

7.  Expression of cyclooxygenase 2 in human malignant melanoma.

Authors:  C Denkert; M Köbel; S Berger; A Siegert; A Leclere; U Trefzer; S Hauptmann
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

8.  Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38.

Authors:  L V Madrid; M W Mayo; J Y Reuther; A S Baldwin
Journal:  J Biol Chem       Date:  2001-03-20       Impact factor: 5.157

9.  ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas.

Authors:  D Vucic; H R Stennicke; M T Pisabarro; G S Salvesen; V M Dixit
Journal:  Curr Biol       Date:  2000-11-02       Impact factor: 10.834

10.  Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.

Authors:  R Ravi; G C Bedi; L W Engstrom; Q Zeng; B Mookerjee; C Gélinas; E J Fuchs; A Bedi
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

View more
  61 in total

1.  Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Authors:  Ali R Jazirehi; James S Economou
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

2.  Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells.

Authors:  Hao Li; Lulu Hui; Wenlin Xu; Huiling Shen; Qiaoyun Chen; Lulu Long; Xiaolan Zhu
Journal:  Oncol Lett       Date:  2011-11-30       Impact factor: 2.967

3.  Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis.

Authors:  Sima Z Torabian; David de Semir; Mehdi Nosrati; Sepideh Bagheri; Altaf A Dar; Sylvia Fong; Yong Liu; Scot Federman; Jeff Simko; Chris Haqq; Robert J Debs; Mohammed Kashani-Sabet
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

4.  Contribution of acidic melanoma cells undergoing epithelial-to-mesenchymal transition to aggressiveness of non-acidic melanoma cells.

Authors:  Silvia Peppicelli; Francesca Bianchini; Eugenio Torre; Lido Calorini
Journal:  Clin Exp Metastasis       Date:  2014-01-28       Impact factor: 5.150

5.  Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression.

Authors:  Silvia Peppicelli; Francesca Bianchini; Alessandra Toti; Anna Laurenzana; Gabriella Fibbi; Lido Calorini
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.

Authors:  Jinming Yang; Snjezana Zaja-Milatovic; Yee-Mon Thu; Francis Lee; Richard Smykla; Ann Richmond
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

7.  Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients.

Authors:  Huajie Bu; Inger Rosdahl; Xiao-Feng Sun; Hong Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-11       Impact factor: 4.553

8.  Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.

Authors:  Anjana Kumari Negi; Archana Bhatnagar; Navneet Agnihotri
Journal:  Inflammopharmacology       Date:  2016-01-09       Impact factor: 4.473

9.  A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFkappaB activity.

Authors:  Daniela Sorriento; Alfonso Campanile; Gaetano Santulli; Eleonora Leggiero; Lucio Pastore; Bruno Trimarco; Guido Iaccarino
Journal:  Mol Cancer       Date:  2009-11-09       Impact factor: 27.401

10.  Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells.

Authors:  Jun Sun; William G Stetler-Stevenson
Journal:  J Mol Signal       Date:  2009-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.